// Biotech and Pharma Therapeutics
Australia to integrate digital health education into university degrees
March 26, 2025 / Digital Health Education / Healthcare Workforce Training / AI in Healthcare / Cirtual Care Integration
Australia is integrating digital health education into university degrees to enhance workforce readiness. Led by the ADHA and ACSALDH, the initiative standardizes digital health curricula, ensuring future healthcare professionals can effectively use AI, virtual care, and digital tools.
11 NZ primary health organisations sign up to National Primary Care Dashboard
March 26, 2025 / New Zealand / Primary Care / PHO Enrollment Trends / Equity in Healthcare / Data Analytics
New Zealand is launching a National Primary Care Dashboard to enhance healthcare decision-making and funding allocation. With 11 PHOs participating, the tool provides national-level insights on service utilization, equity gaps, and workforce distribution, supporting strategic primary care improvements.
Private Medical Practice on Social Media: Viplikes’ Ways to Improve Your Presence and Attract Patients
March 26, 2025 / Medical Social Media Marketing / Healthcare Digital Strategy
Social media is a powerful tool for private medical practices to attract patients and build credibility. Strategies include offering exclusive health content, engaging with niche audiences, and leveraging influencer collaborations. Ethical digital marketing ensures sustainable patient engagement and growth.
Collective Health, Noom Health Offer Integrated GLP-1 Weight Management Solution
March 26, 2025 / GLP-1 Weight Manamgement / Noom Med SmartRx / Obesity Treatment Program
Collective Health and Noom Health have partnered to launch an integrated GLP-1 weight management program. Combining medication access with lifestyle support, the initiative aims to improve obesity treatment while reducing employer healthcare costs through streamlined prescription fulfillment and cost-sharing models.
China to spur innovation through new reimbursement list
March 26, 2024 / China Drug Reimbursement / Innovation / BIOCHINA 2025 / Healthcare Policy Reform
China is considering a new drug reimbursement category (Category C) to involve commercial insurers in co-paying for innovative therapies. This initiative aims to accelerate pharmaceutical innovation and expand patient access to cutting-edge treatments.
// 4th Industrial Revolution
When health accessories grow up, they want to be wearable AI
March 26, 2025 / Wearable AI Healthcare / AI Health Monitoring / Digital Health Devices / Patient Data Privacy / AI in Clinical Care
Wearable AI devices go beyond traditional health trackers by using advanced algorithms to analyze real-time patient data, aiding clinical decisions. Key challenges include sensor reliability, data integration, patient safety, and ethical concerns regarding privacy and bias.
National security leaders: Combating cyber threats from China takes collaboration
March 26, 2025 / Healthcare Cybersecurity Threats / Silk Typhoon / Cyberattacks / Hospital Data Protection / China Cyber Espionage
Chinese state-sponsored cyber groups, including Silk Typhoon, are targeting U.S. healthcare infrastructure, potentially compromising hospital security. National security leaders stress collaboration between government and industry to mitigate risks, protect critical data, and prevent disruptions in healthcare operations.
Physician Sentiment on the Rise, AI Adoption Grows, But Challenges Remain
March 26, 2025 / Physician Sentiment Survey / AI in Healthcare / Physician Burnout
Physician sentiment is improving, with fewer doctors considering leaving medicine. AI adoption is rising, particularly for documentation and administrative tasks. However, challenges persist, including interoperability issues, financial concerns, and regulatory burdens, impacting physician stress and healthcare efficiency.
Wise Hospice Options uses AI to reduce e-prescribe time from 20 seconds to 2
March 26, 2025 / AI in Healthcare / E-prescribing Technology / Hospice Medication Management / Clinical Workflow Optimization
Wise Hospice Options implemented AI-powered e-prescribing with DrFirst, reducing processing time from 20 to 2 seconds. The AI codifies medications, allergies, and sigs, improving accuracy, reducing manual entry, and enhancing workflow efficiency in hospice medication management.
VisiQuate Acquires AI-Powered RCM Automation Platform Rotera
March 26, 2025 / Ai in Revenue Cycle Management / Healthcare Automation / Predictive Analytics in RCM / AI-driven Financial Optimization
VisiQuate has acquired Rotera to enhance AI-driven revenue cycle management (RCM), optimizing cash flow and reducing administrative burdens in healthcare. The integration strengthens VisiQuate’s automation suite, Ana, enabling predictive analytics and streamlined financial operations for healthcare organizations.
// Business & Markets
Alcon Buys Majority Stake in Aurion to Advance Eye Disease Treatment
March 26, 2025 / Alcon Aurion Biotech / Corneal Edema Treatment / AURN001 Clinical Trials / Eye Disease Cell Therapy
Alcon acquired a majority stake in Aurion Biotech to advance AURN001, a novel cell therapy for corneal edema linked to endothelial disease. Aurion, which received FDA breakthrough and regenerative medicine designations, will begin Phase 3 trials in 2024.
Despite raising $1B over past 5 years, ElevateBio lets go of 17% of workforce
March 26, 2025 / Elevate Bio Layoffs / Gene Therapy Manufacturing / Life Edit Gene Editing / BaseCamp Biotech / Huntington’s Disease Treatment
ElevateBio, a cell and gene therapy company, has laid off 17% of its workforce despite raising $1B in recent years. The restructuring focuses on its BaseCamp manufacturing and Life Edit gene editing platforms, which develop therapies for Huntington’s and rare diseases.
Potential federal budget cuts won’t rock Gilead’s HIV boat too much: analystss
March 26, 2025 / Gilead HIV Drug Portfolio / Medicaid Budget Cuts / PrEP Funding / Biktarvy Sales
Gilead’s HIV drug portfolio, including Biktarvy and upcoming PrEP therapy lenacapavir, faces minimal risk from potential federal budget cuts. However, reductions in Medicaid and the 340B AIDS Drug Assistance Program could impact revenue. Analysts caution ongoing monitoring of policy changes.
Uptiv Health partners with Lamar Health to expand AI automation
March 26, 2025 / AI in Healthcare / Infusion Therapy Automation / Prior Authorization AI / Chronic Care Management / Specialty Medication Approvals
Uptiv Health is partnering with Lamar Health to integrate AI automation into referral intake and prior authorization processes for infusion therapy. This collaboration aims to streamline workflows, reduce delays, and improve access to specialty medications for patients with chronic conditions.
Epic Veterans Launch ProsperityEHR to Tackle Behavioral Health’s Financial Crisis
March 26, 2025 / Behavioral Health HER / AI in Healthcare / Revenue Cycle Management / Telehealth Integration / Mental Health Technology
ProsperityEHR, an AI-powered electronic health record (EHR) platform, launches to optimize revenue cycle management and streamline behavioral health operations. It enhances patient engagement, automates administrative tasks, and integrates seamlessly with insurance, e-prescribing, and telehealth systems for improved financial stability.
// Legal & Regulatory
FDA Approves First-in-Class GSK Antibiotic for Common Type of Urinary Tract Infection
March 26, 2025 / FDA-approved Antibiotic / Urinary Tract Infection Treatment / GSK Blujepa / Antibiotic Resistance
The FDA has approved GSK’s Blujepa (gepotidacin), the first new oral antibiotic for uncomplicated urinary tract infections (uUTIs) in decades. Blujepa targets bacterial DNA replication, reducing drug resistance risks. Phase 3 trials confirmed its efficacy against five UTI-causing pathogens.
First Prader-Willi drug to reduce hunger approved by FDA
March 26, 2025 / Prader-Willi Syndrome Treatment / Vykat XR / Hyperphagia Medication / Soleno Therapeutics
The FDA approved Soleno Therapeutics’ Vykat XR, the first drug for hyperphagia in Prader-Willi syndrome. The extended-release diazoxide formulation reduces insatiable hunger, a key burden of the disease. Approval follows a unique study design after prior Phase 3 trial challenges.
Chlamydia Vaccine Candidate Granted Fast Track Designation by the US FDA
March 26, 2025 / Chlamydia Vaccine Candidate / FDA Fast Track Designation / Sanofi mRNA Vaccine
The FDA granted Fast Track designation to Sanofi’s mRNA chlamydia vaccine candidate, which aims to prevent primary and recurrent infections. With rising asymptomatic cases and antibiotic resistance concerns, the vaccine addresses a critical public health need. A Phase 1/2 trial begins soon.
FDA approves Cabometyx for advanced neuroendocrine tumors
March 26, 2025 / Cabometyx FDA Approval / Advanced Neuroendocrine Tumors / Exelixis Cancer Drug / Targeted Therapy for NET
The FDA approved Exelixis’ Cabometyx (cabozantinib) for advanced neuroendocrine tumors (NET), making it the first targeted therapy for NET patients regardless of tumor location or grade. Approval follows positive Phase III data, with further trials planned in 2025.
EC approves Merck’s Capvaxive for new indication
March 26, 2025 / Capvaxive EC Approval / Pneumococcal Vaccine / Merck Capvaxive / Invasive Pneumococcal Disease
The European Commission approved Merck’s Capvaxive, a 21-valent pneumococcal conjugate vaccine, for preventing invasive pneumococcal disease and pneumonia in adults. Approval was based on Phase III STRIDE trial data, expanding its availability across the EU and beyond.
// Research & Development
Vaccine critic’s apparent selection to head HHS autism study shocks experts
March 26, 2025 / HHS Autism Study / Vaccine Safety / David Geier Controversy / Vaccine Misinformation
The reported selection of vaccine critic David Geier to lead an HHS study on vaccines and autism has alarmed experts. Geier, previously disciplined for practicing medicine without a license, has promoted debunked claims linking thimerosal to autism despite extensive scientific refutation.
Zetomipzomib Yields Positive Phase IIa Trial Results in Autoimmune Hepatitis
March 26, 2025 / Autoimmune Hepatitis Treatment / Zetomipzomib Clinical Trial / AIH Therapy
Kezar Life Sciences’ Phase IIa PORTOLA trial showed that zetomipzomib, a selective immunoproteasome inhibitor, improved biochemical response and steroid tapering in autoimmune hepatitis (AIH) patients. The drug demonstrated a favorable safety profile, offering a potential alternative to long-term corticosteroid therapy.
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program
March 21, 2025 / PNH Treatment / Zeltenibart Clinical Trial / Hemolysis Therapy
Omeros has initiated its Phase 3 trial for zaltenibart (OMS906), an investigational MASP-3 inhibitor for paroxysmal nocturnal hemoglobinuria (PNH). The trial evaluates zaltenibart’s ability to inhibit both intravascular and extravascular hemolysis with infrequent dosing. Results are expected in late 2025.
J&J combo signals new era in EGFR lung cancer with survival win against AstraZeneca’s Tagrisso
March 26, 2025 / EGFR Lung Cancer / NSCLC Treatment / Mariposa Trial
Johnson & Johnson’s Rybrevant-Lazcluze combination significantly reduced the risk of death by 25% compared to AstraZeneca’s Tagrisso in first-line EGFR-mutated non-small cell lung cancer (NSCLC), according to Phase 3 Mariposa trial data. This could redefine standard treatment.
Wave to seek approval of Duchenne drug after mid-stage study data
March 26, 2025 / Duchenne Muscular Dystrophy / Exon Skipping Therapy / FDA Approval
Wave Life Sciences plans to seek FDA approval for its Duchenne muscular dystrophy therapy, WVE-N531, after Phase 2 data showed increased dystrophin expression. The exon-skipping therapy targets exon 53 mutations and may offer a best-in-class treatment option.
// Politics
Trump sparks backlash with cuts to Gavi funding
March 26, 2025 / Gavi Funding Cuts / Global Vaccine Alliance / Trump Administration / Childhood Immunization / Foreign Aid Reduction
The Trump administration plans to cut U.S. funding for Gavi, the global vaccine alliance, jeopardizing immunization programs for children in low-income countries. The cuts include a $2.6 billion pledge, potentially impacting malaria and vaccine procurement efforts.
Analysis-Trump turbulence stalls large pharma and biotech deals, bankers say
March 25, 2025 / Pharma M&A Slowdown / Biotech Deal Stalled / Trump Trade Policies / Healthcare Investments
Uncertainty over the Trump administration’s economic policies, including tariffs and trade disputes, is delaying major pharmaceutical and biotech mergers and acquisitions. Healthcare executives are struggling to navigate shifting policies, stalling deal-making timelines by months or quarters.
Trump tariffs drive pharma manufacturing to US but risk inflation and disruption
March 25, 2025 / Pharma Tariffs Impact / US Drug Manufacturing / Eli Lilly Expansion / Pfizer Trade Policy
New US trade tariffs are pressuring pharma companies like Eli Lilly, Pfizer, and Merck to shift manufacturing domestically, potentially increasing production costs and drug prices. The policy risks supply chain disruptions, drug shortages, and retaliatory tariffs affecting global markets.
Trump administration says it will pull back billions in Covid funding from local health departments
March 26, 2025 / Covid-19 Funding Cuts / Trump Health Policy / CDC Budget Reduction / Pandemic Response Rollback / Public Health Funding
The Trump administration is retracting $11.4 billion in COVID-19 funding from state and local health departments, citing the pandemic’s end. The CDC will begin recovering funds within 30 days, raising concerns about future public health preparedness.
Senate confirms Johns Hopkins surgeon Marty Makary to lead FDA amid turbulence at the agency
March 26, 2025 / FDA Leadership Change / Marty Makary FDA / Vaccine Policy FDA
The Senate confirmed Johns Hopkins surgeon Marty Makary, M.D., as FDA Commissioner amid agency turbulence, including layoffs and leadership exits. Makary will address staffing concerns, vaccine policies, and advisory committee structures while working under HHS Secretary Robert F. Kennedy Jr.